Adverse EventsCommon Grade 3+ adverse events included pneumonitis, which resulted in a death, leading to dosing down-titration for those with lung involvements.
Clinical Trial ResultsOf greatest importance, each of the two PRs lasted at most three months before progression, which we believe is not sufficient durability to constitute clinically meaningful activity.
Safety ConcernsThere was widespread pneumonitis observed in patients with lung involvement, leading to an instance of Grade 5 respiratory failure.